Protalix Biotherapeutics

5:00 PM - 5:15 PM (EDT), Monday, June 5, 2023 ・ Session Room 104B
Protalix is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by our proprietary ProCellEx® plant cell-based protein expression system. Our pipeline consists of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical markets. Protalix is proud to be the first company to gain FDA approval for a plant cell culture expressed protein. Elelyso® (taliglucerase alfa for injection) is Protalix’s first drug product produced by its proprietary ProCellEx® protein expression system, and was approved for marketing by the FDA in May 2012, followed soon after by approval by ANVISA in Brazil, Israel’s Ministry of Health, and other regulatory authorities around the world.
NYSE American
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
102, 115, 119
Development Phase of Primary Product:
NDA Preparation/In Review
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
President & CEO
Protalix Biotheraeutics